Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH 2017 | Targeting non-coding RNAs in leukemia

Ramiro Garzon • 5 Oct 2017
ESH 2017
Acute Myeloid Leukemia

There are currently several novel agents that target non-coding RNAs being tested in pre-clinical studies for the treatment of leukemia. In this video, Ramiro Garzon, MD, from the Ohio State University, Columbus, OH, discusses these exciting candidates and talks about the drug development process. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH).

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Ramiro Garzon

Exportin (XPO1) inhibitors for the treatment of AML
2:12
Exportin (XPO1) inhibitors for the treatment of AML
Ramiro Garzon • 5 Oct 2017
Novel targets for AML
1:21
Novel targets for AML
Ramiro Garzon • 5 Oct 2017

Related Videos

Dapolsertib in AML: results from the Phase I/II DIAMOND-01 trial
8:41
Dapolsertib in AML: results from the Phase I/II DIAMOND-01 trial
Roland Walter • 20 Sep 2026
Combination strategies in AML: triplets, targeted therapies and venetoclax resistance
8:33
Combination strategies in AML: triplets, targeted therapies and venetoclax resistance
Hima Atluri • 20 Sep 2026
How and when to use oral decitabine in AML
12:38
How and when to use oral decitabine in AML
Gail Roboz • 20 Sep 2026
A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
22:07
A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
Amir Fathi • 20 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals